CN1151139C - 二苯基亚乙基化合物的新型杂环类似物 - Google Patents

二苯基亚乙基化合物的新型杂环类似物 Download PDF

Info

Publication number
CN1151139C
CN1151139C CNB998010170A CN99801017A CN1151139C CN 1151139 C CN1151139 C CN 1151139C CN B998010170 A CNB998010170 A CN B998010170A CN 99801017 A CN99801017 A CN 99801017A CN 1151139 C CN1151139 C CN 1151139C
Authority
CN
China
Prior art keywords
compounds
level
diabetes
mouse
accompanying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998010170A
Other languages
English (en)
Chinese (zh)
Other versions
CN1273528A (zh
Inventor
P����¼�
P·尼奥吉
B·纳格
S·麦迪克尔拉
D·德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Calyx Therapeutics Inc
Original Assignee
Calyx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/074,925 external-priority patent/US6245814B1/en
Application filed by Calyx Therapeutics Inc filed Critical Calyx Therapeutics Inc
Publication of CN1273528A publication Critical patent/CN1273528A/zh
Application granted granted Critical
Publication of CN1151139C publication Critical patent/CN1151139C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CNB998010170A 1998-05-08 1999-05-07 二苯基亚乙基化合物的新型杂环类似物 Expired - Fee Related CN1151139C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/074,925 1998-05-08
US09/074,925 US6245814B1 (en) 1998-05-08 1998-05-08 Diphenylethylene compounds
US09/287,237 1999-04-06
US09/287,237 US6331633B1 (en) 1998-05-08 1999-04-06 Heterocyclic analogs of diphenylethylene compounds

Publications (2)

Publication Number Publication Date
CN1273528A CN1273528A (zh) 2000-11-15
CN1151139C true CN1151139C (zh) 2004-05-26

Family

ID=26756222

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998010170A Expired - Fee Related CN1151139C (zh) 1998-05-08 1999-05-07 二苯基亚乙基化合物的新型杂环类似物

Country Status (13)

Country Link
US (1) US6331633B1 (enExample)
EP (1) EP1007039B1 (enExample)
JP (1) JP4577985B2 (enExample)
KR (1) KR100595919B1 (enExample)
CN (1) CN1151139C (enExample)
AT (1) ATE260906T1 (enExample)
AU (1) AU751235C (enExample)
CA (1) CA2295599C (enExample)
DE (1) DE69915223T2 (enExample)
DK (1) DK1007039T3 (enExample)
ES (1) ES2216513T3 (enExample)
PT (1) PT1007039E (enExample)
WO (1) WO1999058127A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041941B2 (en) 1997-04-07 2006-05-09 Patented Medical Solutions, Llc Medical item thermal treatment systems and method of monitoring medical items for compliance with prescribed requirements
US7105552B2 (en) * 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
CA2383347A1 (en) 1999-08-31 2001-03-08 Maxia Pharmaceuticals, Inc. Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes
US20080108825A1 (en) * 1999-11-08 2008-05-08 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
US7323496B2 (en) * 1999-11-08 2008-01-29 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
ES2487897T3 (es) 2000-01-21 2014-08-25 Novartis Ag Combinaciones que consisten de inhibidores de la dipeptidilpeptidasa-IV y agentes antidiabéticos
US20080103302A1 (en) * 2000-02-04 2008-05-01 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
PL373912A1 (en) 2001-03-07 2005-09-19 Incyte San Diego, Inc. Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
AU2002254171A2 (en) 2001-03-08 2002-09-24 Incyte San Diego, Inc. RXR activating molecules
MXPA04000695A (es) 2001-07-23 2005-08-26 Galileo Pharmaceuticals Inc Compuestos citoprotectores, formulaciones farmaceuticas y cosmeticas y metodos.
KR100468429B1 (ko) * 2001-09-07 2005-01-27 주식회사 엔바이오테크놀러지 알파-글루코시다제 저해활성이 있는 소나무 추출물 및 그추출방법
WO2003043998A1 (en) 2001-11-15 2003-05-30 Incyte San Diego Incorporated N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
US7102000B2 (en) 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US7041693B2 (en) 2002-10-04 2006-05-09 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
US7781464B2 (en) * 2003-01-17 2010-08-24 Bexel Pharmaceuticals, Inc. Heterocyclic diphenyl ethers
US7521465B2 (en) * 2003-01-17 2009-04-21 Bexel Pharmaceuticals, Inc. Diphenyl ether derivatives
US6794401B2 (en) * 2003-01-17 2004-09-21 Bexel Pharmaceuticals, Inc. Amino acid phenoxy ethers
AU2004253579B2 (en) 2003-07-01 2010-12-23 Biomol International L.P. Sirt1 modulators for manipulating cells/organism lifespan/stress response
US7087576B2 (en) * 2003-10-07 2006-08-08 Bexel Pharmaceuticals, Inc. Dipeptide phenyl ethers
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US20050171027A1 (en) * 2003-12-29 2005-08-04 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
WO2006079021A2 (en) * 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
WO2006126074A2 (en) * 2005-05-26 2006-11-30 Orchid Research Laboratories Limited Heterocyclic derivatives
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
WO2007042878A1 (en) * 2005-10-07 2007-04-19 Orchid Research Laboratories Limited Novel heterocyclic analogs of biphenyl ethers
KR101016875B1 (ko) * 2006-06-23 2011-02-22 현대중공업 주식회사 밀폐형 방청유 도포장치
CN112209896B (zh) * 2019-07-10 2023-05-16 苏州泽璟生物制药股份有限公司 噻唑烷二酮衍生物以及包含其的药物组合物
EP4205740B1 (en) * 2020-08-28 2025-07-02 Celros Biotech Novel thiohydantoin derivatives and uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3683009A (en) 1968-10-10 1972-08-08 Du Pont {60 , {62 -bis(trifluoromethyl) stilbenes
US3609183A (en) 1969-01-08 1971-09-28 Parke Davis & Co {60 -{8 {11 -(dimethylaminoalkyl)phenyl{9 -4-methoxy-{60 {40 -nitrostilbene compounds
US4312855A (en) 1970-11-16 1982-01-26 Colgate-Palmolive Company Compositions containing aminopolyureylene resin
US4326055A (en) 1977-12-22 1982-04-20 Hoffmann-La Roche Inc. Stilbene derivatives
JPS6045632B2 (ja) 1978-03-09 1985-10-11 三菱化学株式会社 ω−アミノアルコキシスチルベン類及びその酸付加塩
US4284637A (en) 1978-03-09 1981-08-18 Mitsubishi Chemical Ind., Limited Pharmaceutically active 2-(4-aminobutoxy)stilbenes
DE2832213A1 (de) 1978-07-21 1980-01-31 Bayer Ag Stilbenderivate, verfahren zu ihrer herstellung und ihre verwendung als insektizide
JPS5629548A (en) 1979-08-16 1981-03-24 Mitsubishi Chem Ind Ltd Omega-aminoalkoxystilbenes and their acid addition salts
FR2562539B1 (fr) 1984-04-06 1987-04-17 Chauvin Blache Lab Nouveaux derives de l'acide vinyl-4 benzoique, leur procede de preparation et leurs applications en therapeutique et comme ligands
US4716905A (en) 1985-09-25 1988-01-05 Fluorochrome, Inc. Method of retrograde fluorescent labeling of neurons
CA1338645C (en) 1987-01-06 1996-10-15 George R. Pettit Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins"
GB8716650D0 (en) 1987-07-15 1987-08-19 Ici Plc Use of olefinic compounds
US5250562A (en) 1988-02-24 1993-10-05 Hoffmann-La Roche Inc. Stilbene derivatives
CA1340955C (en) 1988-02-24 2000-04-11 Michael Klaus Stilbene derivatives
WO1989008650A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Thiazolidinedione hypoglycemic agents
DE3926148A1 (de) 1989-08-08 1991-02-28 Basf Ag Diarylacetylene, ihre herstellung und verwendung
US5189056A (en) 1989-12-19 1993-02-23 University Of North Carolina At Chapel Hill Protection of moist stratified squamous epithelia against damage from noxious luminal agents
US5162337A (en) 1990-10-05 1992-11-10 Merck & Co., Inc. Animal growth promotion
EP0498095B1 (en) 1991-02-05 1995-01-04 Merrell Dow Pharmaceuticals Inc. Sulfonic stilbene derivatives in the treatment of viral diseases
CH683151A5 (de) 1991-04-24 1994-01-31 Ciba Geigy Ag Antikonzeption bei weiblichen Primaten ohne Beeinflussung des menstruellen Zyklus.
US5171753A (en) 1991-05-15 1992-12-15 A. H. Robins Company, Incorporated Derivatives of 2-amino-1-phenylethanol having antiulcer activity
US5565322A (en) 1991-11-07 1996-10-15 Nanogen, Inc. Hybridization of polynucleotides conjugated with chromophores and fluorophores to generate donor-to donor energy transfer system
US5246936A (en) 1991-12-20 1993-09-21 American Cyanamid Company Methods and compositions containing pesticides and stilbene compounds for enhanced pesticidal activity
NO302471B1 (no) * 1991-12-26 1998-03-09 Sankyo Co Tiazolidinforbindelser og farmasöytisk preparat
US5314693A (en) 1992-02-07 1994-05-24 Kioritz Corporation Pest control chemicals against pine wood nematodes
US5430062A (en) 1992-05-21 1995-07-04 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
EP0640586B1 (en) 1993-03-10 1999-06-09 Morinaga Milk Industry Co., Ltd. Stilbene derivative and stilbene analog derivative, and use thereof
US5731353A (en) 1993-09-08 1998-03-24 Ajinomoto Co., Inc. Stilbene derivatives and pharmaceutical compositions containing them
TW325458B (en) 1993-09-08 1998-01-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer
IT1264988B1 (it) 1993-12-14 1996-10-17 Sigma Prod Chim Composizioni cosmetiche e dermatologiche per la protezione da radiazioni uv contenenti derivati dallo stilbene
TW308598B (enExample) 1994-01-14 1997-06-21 Hoffmann La Roche
JPH08143566A (ja) * 1994-11-25 1996-06-04 Terumo Corp キナゾリン誘導体及びそれを含有する医薬組成物
US5559151A (en) 1994-11-30 1996-09-24 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of chloride channel blockers
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
CA2174582A1 (en) 1995-05-05 1996-11-06 Alexander Chucholowski Sulphuric acid esters of amino-sugars
US5716928A (en) 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5770620A (en) 1995-06-19 1998-06-23 Ontogen Corporation Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors
US5733909A (en) 1996-02-01 1998-03-31 Merck Frosst Canada, Inc. Diphenyl stilbenes as prodrugs to COX-2 inhibitors
US5827898A (en) 1996-10-07 1998-10-27 Shaman Pharmaceuticals, Inc. Use of bisphenolic compounds to treat type II diabetes

Also Published As

Publication number Publication date
ES2216513T3 (es) 2004-10-16
CN1273528A (zh) 2000-11-15
DE69915223T2 (de) 2005-01-27
EP1007039A1 (en) 2000-06-14
CA2295599A1 (en) 1999-11-18
HK1028348A1 (en) 2001-02-16
CA2295599C (en) 2009-01-20
AU751235B2 (en) 2002-08-08
KR20010021615A (ko) 2001-03-15
ATE260906T1 (de) 2004-03-15
KR100595919B1 (ko) 2006-07-03
JP4577985B2 (ja) 2010-11-10
JP2002514598A (ja) 2002-05-21
US6331633B1 (en) 2001-12-18
DE69915223D1 (de) 2004-04-08
AU3974199A (en) 1999-11-29
AU751235C (en) 2004-06-24
EP1007039B1 (en) 2004-03-03
PT1007039E (pt) 2004-07-30
WO1999058127A1 (en) 1999-11-18
DK1007039T3 (da) 2004-07-12
EP1007039A4 (en) 2002-05-22

Similar Documents

Publication Publication Date Title
CN1151139C (zh) 二苯基亚乙基化合物的新型杂环类似物
CN1248683C (zh) 二肽基肽酶iv抑制剂在制备治疗2型糖尿病的药物中的用途
EA020849B1 (ru) Применение 1,3-дифенилпроп-2-ен-1-оновых производных для лечения заболеваний печени
US6245814B1 (en) Diphenylethylene compounds
AU784702B2 (en) Novel compounds to treat diabetes and associated conditions
US6448450B1 (en) 1-(3,5-dimethoxyphenyl)-2-(4-hydroxyphenyl)-ethylene for diabetes treatment
Yin et al. NO-1886 decreases ectopic lipid deposition and protects pancreatic beta cells in diet-induced diabetic swine
CN1194674C (zh) 新的二苯乙烯化合物
JP2009058500A (ja) 血糖値を降下させる物質の評価方法、スクリーニング方法及び製造方法
KR101391905B1 (ko) 물질대사 장애의 치료용 화합물
WO2023221418A1 (zh) 一种促进胰岛α细胞转化为β细胞的诱导方法及其应用
CN1358096A (zh) 糖尿病治疗剂
CN1785433A (zh) 一种ⅱ型糖尿病动物模型的制备方法
Hui et al. Gene expression of adiponectin and adiponectin receptor 1 in type 2 diabetic rats and the relationship with the parameters of glucose and lipid metabolism
CN113209083A (zh) 一种治疗代谢综合征的药物
HK1028348B (en) Novel heterocyclic analogs of diphenylethylene compounds
CN1291721C (zh) 蒜糖醇在制备糖尿病药物中的应用
CN120733011A (zh) Lgmn蛋白在制备预防和/或治疗mash的药物中的应用
HK1087038A (en) Composition and method for treating diabetes
CN111093644A (zh) 葡萄糖消耗促进剂和糖酵解促进剂
JPWO1996003148A1 (ja) 糖尿病の治療方法および治療剤
HK1045121B (en) Remedies for diabetes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: ZERIX COMPANY

Free format text: FORMER OWNER: CALYX THERAPEUTICS INC.

Effective date: 20040827

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20040827

Address after: American California

Patentee after: Calyx Therapeutics Inc.

Address before: American California

Patentee before: Calyx Therapeutics Inc.

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20040526

Termination date: 20130507